Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient

• Main Authors: S. Morelli, E. Puxeddu
• Format: Article
• Language: English
• Published: BioExcel Publishing Ltd 2017-07-01
• Series: Drugs in Context
• Subjects: lenvatinib; papillary thyroid carcinoma; poorly differentiated thyroid carcinoma; RAI refractory; sorafenib; sunitinib
• Online Access: http://www.drugsincontext.com/long-term-efficacy-safety-fourth-line-multikinase-inhibitor-treatment-lenvatinib-young-papillary-thyroid-carcinoma-patient/

Lenvatinib, a multikinase inhibitor, is approved for the treatment of patients with radioiodine-refractory metastatic thyroid cancer on the basis of a Phase III, prospective, double-blind, randomized, placebo-controlled trial that showed longer progression-free survival in the drug-treated arm. Here, we report the case of a young papillary thyroid cancer patient, pretreated with three other kinase inhibitors, who achieved a long-term clinical benefit from lenvatinib in the fourth-line setting.